Open Access
Article
Proteomics/peptidomics tools to find CSF biomarkers for neurodegenerative diseases
Ann Westman-Brinkmalm1,Ulla Ruetschi1,Erik Portelius1,Ulf Andreasson1,Gunnar Brinkmalm1,Gosta Karlsson1,Sara Hansson1,Henrik Zetterberg1,Kaj Blennow1
1
Institute of Neuroscience and Physiology, Department of Psychiatry and Neuochemistry, The Sahlgrenska Academy at Goteborg University, Sweden. ann.brinkmalm@neuro.gu.se
DOI: 10.2741/3341 Volume 14 Issue 5, pp.1793-1806
Published: 01 January 2009
Abstract

Neurodegenerative diseases are characterized by premature neuronal loss in specific brain regions. During the past decades our knowledge on molecular mechanisms underlying neurodegeneration has increased immensely and resulted in promising drug candidates that might slow down or even stop the neuronal loss. These advances have put a strong focus on the development of diagnostic tools for early or pre-clinical detection of the disorders. In this review we discuss our experience in the field of neuroproteomics/peptidomics, with special focus on biomarker discovery studies that have been performed on CSF samples from well-defined patient and control populations.

Share and Cite
Ann Westman-Brinkmalm, Ulla Ruetschi, Erik Portelius, Ulf Andreasson, Gunnar Brinkmalm, Gosta Karlsson, Sara Hansson, Henrik Zetterberg, Kaj Blennow. Proteomics/peptidomics tools to find CSF biomarkers for neurodegenerative diseases. Frontiers in Bioscience-Landmark. 2009. 14(5); 1793-1806.